Virtual Business Models - Bryder, Karin;Malmborg-Hager, Anki;Söderlind, Eskil
109,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Gebundenes Buch

Virtual Business Models: Entrepreneurial Risks and Rewards focuses on companies with technology development, offering inspiration, guidance, and hands-on advice on how to utilize the potential of a virtual company format.
The book provides an overview of key aspects of the company's activities, putting them into a comprehensive structure. In addition, both the rewards and risks of using the virtual company format are explored.
The virtual company format is here defined as a company with a small dedicated core staff. The company's development is performed by strategic alliances with…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Virtual Business Models: Entrepreneurial Risks and Rewards focuses on companies with technology development, offering inspiration, guidance, and hands-on advice on how to utilize the potential of a virtual company format.

The book provides an overview of key aspects of the company's activities, putting them into a comprehensive structure. In addition, both the rewards and risks of using the virtual company format are explored.

The virtual company format is here defined as a company with a small dedicated core staff. The company's development is performed by strategic alliances with external resource providers. In this way, the utilization of financial resources can be optimized with cost-effective product development. The book explores this concept and why it is attractive in a start-up phase for both companies who want to remain virtual and those that eventually want to develop into integrated traditional companies.
Autorenporträt
Karin Bryder has extensive experience as project manager within the fields of pharmaceuticals and med tech and has acted as IP manager and CEO of companies using a virtual company format. Karin holds a PhD in Medical Science with focus on Immunology. Her academic work also includes studies of DNA vaccines and virus genetics.

Anki Malmborg has extensive experience from business development within life science. She has worked for several small biotech companies, both as CEO and board member and as an investment director. Anki has a M. Sc. in Chemical Engineering, holds a Ph.D. in Immunotechnology from Lund University and a Pharma-MBA from Falconbury.Eskil Söderlind has extensive experience from the business area with focus on life science He has past and present experience as Investment Director, CEO and as board member. Eskil´s formal education includes a PhD in molecular biology from Uppsala and an associate professorship at Lund University; he also has an executive Master of Business Administration (MBA) diploma